BCL2 and hepatocellular carcinoma: A study conducted on human liver cancer cells (HCC) investigated the protective ability of Bcl-2 in a recombinant vector against doxorubicin-mediated cell death (0.01, 0.1 and 1μg/mL doxorubicin) [4].